Viking Q3 Loss Widens to $183.2M as R&D Hits $166.8M; Cash $960M
VKTX is trading near its 52-week low of $23.82 (2.4% above the low).
Summary
Viking reported a Q3 2026 net loss of $183.2 million ($1.55/share) on R&D of $166.8 million, and ended the quarter with $960 million in cash. The company also started the SUNRISE oral Phase 3 program and Part 2 of its maintenance dosing study.
Key Events · Earnings and Guidance · VKTX
-
Q3 Loss Widens on Phase 3 Spend
Net loss was $183.2 million, or $1.55 per share, versus $90.8 million, or $0.81 per share, a year earlier; R&D rose to $166.8 million from $90.0 million.
-
Cash of $960 Million After Raise
Quarter-end cash, cash equivalents and short-term investments totaled $960 million, including roughly $550 million in net proceeds from the September concurrent offerings.
-
SUNRISE Oral Phase 3 Underway
The SUNRISE Phase 3 program for oral VK2735 was initiated, with SUNRISE-1 and SUNRISE-2 each targeting enrollment of 560 adults on 68 weeks of once-daily dosing.
-
VANQUISH Data Expected 2027
Both VANQUISH Phase 3 studies of subcutaneous VK2735 continue on track and are expected to complete in 2027, with extension studies to begin in 1Q27.
Analysis · VKTX · Life Sciences
The balance sheet is the real story here: $960 million in cash after the September raise funds the VANQUISH and SUNRISE Phase 3 programs plus pre-commercial build-out, even as the quarterly loss more than doubled year over year on ramped Phase 3 spending. With the stock near its 52-week low, the market is focused on trial execution and the 2027 VANQUISH readouts rather than the loss itself. The quarter also brought the SUNRISE oral Phase 3 start and the Part 2 maintenance study, extending the VK2735 franchise across formulations and dosing schedules.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31.1% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $24.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $23.82 to $43.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.